Long-term data presented by Dr. Charles Rudin during WCLC 2022 showed significant OS benefit for patients with extensive stage SCLC on pembrolizumab combination versus placebo.

During WCLC 22, Dr. Renelle Myers demonstrated the importance of considering long-term cumulative exposure to air pollutants when assessing individual lung cancer risk.

Dr. Solange Peters showed 24-month overall survival rates were higher with tremelimumab, durvalumab, and chemotherapy versus chemotherapy alone across all subgroups, including those with KRAS, STK11, and KEAP1 mutations.

In a Q&A with ILCN, Dr. Karen Kelly looks back at the moments that made lasting impressions and the presentations with the power to change the practice of thoracic oncology.

Research presented during WCLC 2022 shows patient-centered summaries may help potential participants to better understand the benefits and risks of clinical trials.

Experts evaluate available evidence comparing various strategies, including prophylactic cranial irradiation vs. surveillance, stereotactic radiosurgery vs. whole-brain radiotherapy, and more.

Experts reviewed data that show smoking can reduce innate immunity and suppress the efficacy of anti-cancer agents, leading to poorer outcomes for patients who continue to smoke after their cancer diagnosis.

The SHAWL study showed most women with lung cancer have little or no interest in sexual activity and experience increased pain and discomfort during sex following their diagnoses.

Advances in radiotherapy, robotic surgery, and artificial intelligence promise to change the practice of thoracic oncology.

Profession challenged to double survival rates within 5 years. Improving screening, reducing barriers to treatments will be key.